Johnson & Johnson: Beat — EPS $2.59, Revenue $25.4B
Earnings BeatQ3 2026 · Pre-market
@trystockwhiz
Did Johnson & Johnson (JNJ) beat earnings today?
Yes, Johnson & Johnson (JNJ) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+2.37% surprise
$2.59Actual
Expected: $2.53
vs. year ago -7.5%
Total Revenue+0.07% surprise
$25.4BActual
Expected: $25.38B
vs. year ago +5.9%
Released Oct 13 · 6:20 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $25.40B | $23.99B | +5.9% |
| └─Innovative Medicine | $16.76B | $15.56B | +7.7% |
| └─MedTech | $8.64B | $8.43B | +2.5% |
| Net Earnings | $210.00M | $5.15B | -95.9% |
| GAAP Diluted EPS | $0.09 | $2.12 | -95.8% |
| Adjusted Net Earnings | $6.34B | $6.80B | -6.8% |
| Adjusted Diluted EPS | $2.59 | $2.80 | -7.5% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY2026 Outlook |
|---|---|---|
| Adjusted Operational Sales | — | 6.4%-6.8% / 6.6% midpoint (prev. 6.2%-6.8% / 6.5% midpoint) |
| Operational Sales | — | $100.5B-$100.9B / $100.7B midpoint (+6.7%-7.1% YoY / 6.9% midpoint, prev. $100.3B-$100.9B / $100.6B midpoint; +6.5%-7.1% YoY / 6.8% midpoint) |
| Estimated Reported Sales | — | $101.0B-$101.4B / $101.2B midpoint (+7.2%-7.6% YoY / 7.4% midpoint, prev. $100.8B-$101.4B / $101.1B midpoint; +7.0%-7.6% YoY / 7.3% midpoint) |
| Adjusted Operational EPS | — | $10.95-$11.05 / $11.00 midpoint (+1.5%-2.4% YoY / 2.0% midpoint, prev. $10.86-$11.01 / $10.94 midpoint; +0.7%-2.1% YoY / 1.4% midpoint) |
| Adjusted EPS | — | $11.05-$11.15 / $11.10 midpoint (+2.4%-3.3% YoY / 2.9% midpoint, prev. $10.96-$11.11 / $11.04 midpoint; +1.6%-3.0% YoY / 2.3% midpoint) |
Business Highlights
- ➤Received FDA market authorization for the OTTAVA robotic surgical system.
- ➤Received CE Marking for ACUVUE OASYS MAX Reusable contact lenses.
- ➤FDA approved IMAAVY for warm autoimmune hemolytic anemia.
- ➤RYBREVANT FASPRO received FDA Priority Review for advanced head and neck cancer.
- ➤Reported positive Phase 3 results in multiple myeloma.
- ➤Completed the acquisition of Firefly Bio, Inc. for next-generation oncology innovation.
- ➤Announced a collaboration with Sail Biomedicines for in vivo CAR-T programs.
- ➤Announced a proposed resolution of ovarian talc litigation.
- ➤Jennifer Taubert will retire; Tom Cavanaugh appointed Worldwide Chairman, Innovative Medicine.
- ➤MONARCH QUEST 3 advanced the latest in robotically-assisted bronchoscopy.
- ➤CARVYKTI delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients.
- ➤TECVAYLI + TALVEY reduced risk of progression or death by 89% in earlier-line multiple myeloma.
Management Commentary
Joaquin Duato, Chairman and Chief Executive Officer
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio.”
Joaquin Duato, Chairman and Chief Executive Officer
“In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”